Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ: ESPR )

2.275 +0.015 (+0.66%)
Streaming Delayed Price Updated: 10:10 AM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
Esperion Reports First Quarter 2024 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming May Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report First Quarter 2024 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
From Esperion Therapeutics, Inc.
Via GlobeNewswire
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
From Esperion Therapeutics
Via Business Wire
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
From Esperion Therapeutics, Inc.
Via GlobeNewswire
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Third Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2023 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
American College of Cardiology Program to Increase Cholesterol Screenings
From Esperion Therapeutics, Inc.; The American College of Cardiology
Via GlobeNewswire
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.